التفاصيل البيبلوغرافية
| العنوان: |
Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome. |
| المؤلفون: |
Sobue, Yoko1, Nishi, Kentaro2 nishi-k@ncchd.go.jp, Kamei, Koichi2, Inoki, Yuta2,3, Osaka, Kei2,4, Kaneda, Tomoya2,4, Akiyama, Misaki2,5, Sato, Mai2, Ogura, Masao2, Ishikura, Kenji6, Ishiguro, Akira1, Ito, Shuichi2,5 |
| المصدر: |
Pediatric Nephrology. Jun2024, Vol. 39 Issue 6, p1825-1835. 11p. |
| مصطلحات موضوعية: |
*STEROID drugs, *RISK assessment, *IMMUNOSUPPRESSIVE agents, *DRUG therapy, *RETROSPECTIVE studies, *RITUXIMAB, *DESCRIPTIVE statistics, *NEPHROTIC syndrome, *LONGITUDINAL method, *MEDICAL records, *ACQUISITION of data, *DISEASE relapse, *CONFIDENCE intervals, *DRUG resistance, *DISEASE risk factors, *ADOLESCENCE, *CHILDREN |
| مستخلص: |
Background: Despite adverse events associated with the long-term use of immunosuppressants, their long-term discontinuation remains challenging in children with idiopathic nephrotic syndrome. Relapse and resumption of immunosuppressants after discontinuation and associated risk factors were analyzed. Methods: This single-center retrospective cohort study included children with frequently relapsing/steroid-dependent nephrotic syndrome (FRNS/SDNS) or steroid-resistant nephrotic syndrome (SRNS) who initiated immunosuppressant treatment between 2010 and 2020. Patients treated with immunosuppressants for less than two years, those with genetic SRNS, and those with continuation of immunosuppressants were excluded. Results: Sixty-eight patients with FRNS/SDNS or SRNS discontinued immunosuppressants. Discontinuation of immunosuppressants was more frequently tried in patients with less relapse on initial immunosuppressants and less rituximab administration. Of 68 patients who discontinued immunosuppressants, 45 (66%) relapsed and 31 (46%) resumed immunosuppressants with a median follow-up of 39.8 months (IQR 24.6–71.2 months) after discontinuation. The relapse-free survival rates were 40.0%, 35.3%, and 35.3% in 1, 2, and 3 years from discontinuation of immunosuppressants, respectively. Relapse on initial immunosuppressants (HR 2.038, 95%CI 1.006–4.128, P = 0.048) and the relapse-free interval before discontinuation of immunosuppressants (HR 0.971, 95%CI 0.944–0.998, P = 0.037) were significant risk factors associated with relapse after the discontinuation of immunosuppressants, adjusting for sex, age at immunosuppressant treatment initiation, SRNS, and rituximab use. Conclusions: Long-term discontinuation of immunosuppressants can be feasible in patients without a relapse on initial immunosuppressants, those with longer relapse-free interval before discontinuation of immunosuppressants, and those without a relapse for one year after discontinuation of immunosuppressants. Trial registration: Not applicable. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
